The Hong Kong College of Obstetricians and  Gynaecologists (HKCOG) has recently updated its guidelines on the prevention and screening of cervical cancer.¹ The latest recommendations incorporated recent evidence on the role of co-testing with human papillomavirus (HPV)-based screening and cytology-based screening.¹ In an interview with Omnihealth Practice, Dr. Wong, Ching-Yin Grace shared the rationale behind co-testing as the preferred testing modality in  The Family Planning Association of Hong Kong as it offers concurrent triaging. The combination of sensitivity with HPV tests and the specificity with cytology tests allows for a more lenient screening schedule for women in Hong Kong without compromising the benefit of cervical cancer detection.

STUDY DESIGN Dostarlimab in conjunction with carboplatin-paclitaxel (CP) has previously been shown to significantly improve progression-free survival (PFS) and overall survival (OS) outcomes compared with CP alone in patients with primary advanced or recurrent endometrial cancer (EC).1 This has led

STUDY DESIGN For over 2 decades, locally advanced cervical cancer (LACC) has been treated with external beam radiotherapy (EBRT) and concurrent chemotherapy, followed by brachytherapy.1 However, the toxicity associated with these treatments along with the burden of the disease itself have led to a

To date, cervical cancer remains a major global health issue.1 In 2020, there were 604,000 newly diagnosed cases and 324,000 deaths, 90% of which occurred in low- and middle-income countries.1 Chemoradiation therapy (CRT) has been considered the standard of care (SOC) in locally advanced diseases fo

A recent local study published in Nature Cell Biology has revealed transcriptomic and epigenomic dysregulation on the maternal-fetal interface (MFI) caused by maternal severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection.¹ Jointly conducted by the Department of Obstetrics and Gynecology at the Chinese University of Hong Kong (CUHK) and the Division of Life Science at the Hong Kong University of Science and Technology (HKUST), this research was first of its kind in assessing epigenetic alterations for coronavirus disease 2019 (COVID-19)-associated pregnancy.¹  

Cervical cancer (CC) is the 4th most common female cancer globally, claiming more than 300,000 women’s lives in 2018.¹ In Hong Kong, the incidence of CC remained high at around 7 per 100,000 women in 2019, which was still below the World Health Organization’s (WHO) target of fewer than 4 per 100,000

The association between herpes zoster (HZ) and an increased risk of stroke is well documented.^1,2 A large cohort study including 1.38 million Medicare beneficiaries, reported a lower incidence of ischemic and hemorrhagic stroke in the recipients of Zoster Vaccine Live (ZVL).³

Human papillomavirus (HPV) is the most common sexually transmitted infection. In total, more than 40 types of HPV can be transmitted through direct sexual contact, including those types classified as high risk for the development of cervical cancer.¹